Fabio Chianelli
Chief Executive Officer at PHARMATHER HOLDINGS LTD.
Net worth: 3 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Carlo Sansalone | M | - | 10 years | |
| Christian Scovenna | M | 50 | 5 years | |
| Michael Frank | M | - | 5 years | |
| William Jackson | M | - |
Revive Therapeutics, Inc.
 Revive Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Revive Therapeutics Ltd., Revive Therapeutics, Inc. is a specialty life sciences company based in North York, CA. The company focuses on the research and development of therapeutics for rare disorders and infectious diseases. Revive Therapeutics' cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. Revive Therapeutics was acquired by Mercury Capital II Ltd. on January 06, 2014 for $4.67 million. The Canadian company was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is also exploring the use of bucillamine for the potential treatment of infectious diseases, including COVID-19. The company was founded by Fabio Chianelli. Revive recently acquired Psilocin Pharma Corp. to advance psilocybin-based therapeutics in various diseases and disorders. | 10 years |
| Ming Jang | M | 63 | 2 years | |
| Carmelo Marrelli | M | 53 |
Revive Therapeutics, Inc.
Revive Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Revive Therapeutics Ltd., Revive Therapeutics, Inc. is a specialty life sciences company based in North York, CA. The company focuses on the research and development of therapeutics for rare disorders and infectious diseases. Revive Therapeutics' cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. Revive Therapeutics was acquired by Mercury Capital II Ltd. on January 06, 2014 for $4.67 million. The Canadian company was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is also exploring the use of bucillamine for the potential treatment of infectious diseases, including COVID-19. The company was founded by Fabio Chianelli. Revive recently acquired Psilocin Pharma Corp. to advance psilocybin-based therapeutics in various diseases and disorders. | 11 years |
| Beverly Incledon | M | - | 4 years | |
| Andrew Lindzon | M | 63 | 5 years | |
| Jing Peng | M | 47 | 3 years | |
| Joshua Herman | M | - | 5 years | |
| Elyssia Patterson | F | 38 | 3 years | |
| Owen van Cauwenberghe | M | - | - | |
| Andrew Newbury | M | - | - | |
| Bassma Ghali | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Craig Leon | M | 56 | 6 years | |
| Emily Davis | F | 52 | 2 years | |
| Robbie Grossman | M | 50 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 17 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Fabio Chianelli
- Personal Network
